

Status: Currently Official on 17-Feb-2025  
Official Date: Official as of 01-Nov-2024  
Document Type: USP Monographs  
DocId: GUID-5E9DB10F-4720-4599-A1D0-70B64397A7EE\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M25160\\_03\\_01](https://doi.org/10.31003/USPNF_M25160_03_01)  
DOI Ref: h4ivm

© 2025 USPC  
Do not distribute

# Dicyclomine Hydrochloride Tablets

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click <https://www.uspnf.com/rb-dicyclomine-hcl-tabs-20241025>.

## DEFINITION

Dicyclomine Hydrochloride Tablets contain NLT 93.0% and NMT 107.0% of the labeled amount of dicyclomine hydrochloride ( $C_{19}H_{35}NO_2 \cdot HCl$ ).

## IDENTIFICATION

• **A.**

**Sample:** Transfer a portion of finely powdered Tablets, equivalent to 100 mg of dicyclomine hydrochloride, to a separator containing 10 mL of [water](#) and 1 mL of [hydrochloric acid](#). Extract the aqueous acid solution with two 30-mL portions of [chloroform](#), transfer the chloroform extracts to a second separator containing 20 mL of [water](#) and 1 mL of [sodium hydroxide](#) solution (1 in 10), and shake. Filter the chloroform layer through [anhydrous sodium sulfate](#) into a suitable container. Add 3 mL of a freshly prepared 1-in-20 solution of [acetyl chloride](#) in anhydrous [methanol](#), prepared by cautiously adding [acetyl chloride](#) dropwise to anhydrous [methanol](#) with stirring. Evaporate under reduced pressure at room temperature until the residue has been thoroughly dried. Use the residue so obtained to prepare a potassium bromide dispersion.

**Standard:** Use a similarly prepared potassium bromide dispersion of [USP Dicyclomine Hydrochloride RS](#).

**Acceptance criteria:** The IR absorption spectrum of the *Sample* exhibits maxima and minima at the same wavelengths as those of the *Standard*.

• **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

## ASSAY

• **PROCEDURE**

**Buffer:** Dissolve 2.72 g of [monobasic potassium phosphate](#) in 900 mL of [water](#), adjust with 10% [sodium hydroxide](#) to a pH of  $7.5 \pm 0.1$ , and dilute with [water](#) to 1000 mL.

**Mobile phase:** [Acetonitrile](#) and *Buffer* (70:30)

**Diluent:** [Acetonitrile](#) and [water](#) (70:30)

**Standard solution:** 0.4 mg/mL of [USP Dicyclomine Hydrochloride RS](#) in *Diluent*. [NOTE—This solution is stable for at least 2 days.]

**Sample solution:** Transfer NLT 20 Tablets to a tared container, and determine the average Tablet weight. Grind the Tablets to a fine powder using a glass mortar and pestle. Transfer a portion of the powder, equivalent to 20 mg of dicyclomine hydrochloride, to a 50-mL volumetric flask, add 2.0 mL of [water](#), and sonicate for at least 2 min to disperse the sample. Add 35 mL of [acetonitrile](#), sonicate for at least 5 min, and shake by mechanical means for at least 30 min. Add 10 mL of [water](#), allow the solution to equilibrate to room temperature, then dilute with [water](#) to volume. Centrifuge a portion of this solution in a 15-mL glass centrifuge tube for at least 5 min. Use the clear supernatant.

### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 215 nm

**Column:** 4.6-mm  $\times$  15-cm; 3.5- $\mu$ m packing [L7](#)

**Flow rate:** 1 mL/min

**Injection volume:** 50  $\mu$ L

### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 1.5

**Relative standard deviation:** NMT 1.5%

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of dicyclomine hydrochloride ( $C_{19}H_{35}NO_2 \cdot HCl$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak area of dicyclomine from the *Sample solution*

$r_s$  = peak area of dicyclomine from the *Standard solution*

$C_s$  = concentration of [USP Dicyclomine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_u$  = nominal concentration of dicyclomine hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** 93.0%–107.0%

## PERFORMANCE TESTS

**Change to read:**

- [DISSOLUTION \(711\)](#).

### ▲Test 1▲ (RB 1-Nov-2024)

**Medium:** 0.01 N [hydrochloric acid](#); 500 mL

**Apparatus 2:** 50 rpm

**Time:** 45 min

Determine the amount of dicyclomine hydrochloride ( $C_{19}H_{35}NO_2 \cdot HCl$ ) dissolved by employing the following method.

**Buffer:** Dissolve 2.72 g of [monobasic potassium phosphate](#) in 450 mL of [water](#), adjust with 10% [sodium hydroxide](#) to a pH of  $7.5 \pm 0.1$ , and dilute with [water](#) to 500 mL.

**Mobile phase:** Prepare as directed in the Assay.

**Diluent:** [Acetonitrile](#) and *Buffer* (1:1)

**Standard stock solution:** 40 µg/mL of [USP Dicyclomine Hydrochloride RS](#) in *Medium*

**Standard solution:** Mix 25.0 mL of *Standard stock solution* and 25.0 mL of *Diluent*.

**Sample solution:** Pass a portion of the solution under test through a glass microfiber filter of 0.7-µm pore size. Transfer 5.0 mL of the filtrate to a suitable flask, and add 5.0 mL of *Diluent*.

### Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

**Mode:** LC

**Detector:** UV 215 nm

**Column:** 4.6-mm × 15-cm; 3.5-µm packing [L7](#)

**Flow rate:** 1 mL/min

**Injection volume:** 250 µL

### System suitability

**Sample:** *Standard solution*

### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of dicyclomine hydrochloride ( $C_{19}H_{35}NO_2 \cdot HCl$ ) dissolved:

$$\text{Result} = (r_u/r_s) \times (C_s/L) \times V \times D \times 100$$

$r_u$  = peak response of dicyclomine from the *Sample solution*

$r_s$  = peak response of dicyclomine from the *Standard solution*

$C_s$  = concentration of [USP Dicyclomine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$L$  = label claim (mg/Tablet)

$V$  = volume of *Medium*, 500 mL

$D$  = dilution factor for the *Sample solution*

**Tolerances:** NLT 75% (Q) of the labeled amount of dicyclomine hydrochloride ( $C_{19}H_{35}NO_2 \cdot HCl$ ) is dissolved.

### ▲Test 3: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 3*.

**Medium:** 0.1 N [hydrochloric acid](#); 500 mL

**Apparatus 2:** 50 rpm

**Time:** 30 min

**Buffer:** Dissolve 2.72 g of [potassium phosphate, monobasic](#) in 450 mL of [water](#), adjust with 10% [sodium hydroxide](#) to a pH of 7.5 and dilute with [water](#) to 500 mL.

**Mobile phase:** [Acetonitrile](#) and *Buffer* (70:30)

**Diluent:** [Acetonitrile](#) and *Buffer* (50:50)

**Standard stock solution:** 0.04 mg/mL of [USP Dicyclomine Hydrochloride RS](#) in *Medium*. Sonicate to dissolve, if necessary.

**Standard solution:** 0.02 mg/mL of [USP Dicyclomine Hydrochloride RS](#) from *Standard stock solution* in *Diluent*

**Sample solution:** Pass a portion of the solution under test through a suitable filter of 0.45-µm pore size, discarding an appropriate volume of filtrate so that a consistent result can be obtained. Dilute the solution to a concentration similar to that of the *Standard solution* in *Diluent*.

**Chromatographic system**

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 215 nm

**Column:** 4.6-mm × 15-cm; 3.5-µm packing [L7](#)

**Flow rate:** 1 mL/min

**Injection volume:** 250 µL

**Run time:** NLT 1.7 times the retention time of dicyclomine

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of dicyclomine hydrochloride ( $C_{19}H_{35}NO_2 \cdot HCl$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times D \times (1/L) \times 100$$

$r_U$  = peak response of dicyclomine from the *Sample solution*

$r_S$  = peak response of dicyclomine from the *Standard solution*

$C_S$  = concentration of [USP Dicyclomine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$V$  = volume of *Medium*, 500 mL

$D$  = dilution factor for the *Sample solution*

$L$  = label claim (mg/Tablet)

**Tolerances:** NLT 80% (Q) of the labeled amount of dicyclomine hydrochloride ( $C_{19}H_{35}NO_2 \cdot HCl$ ) is dissolved.▲ (RB 1-Nov-2024)

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

**IMPURITIES**

- **LIMIT OF DICYCLOMINE RELATED COMPOUND A**

**Buffer:** Dissolve 2.72 g of [monobasic potassium phosphate](#) in 900 mL of [water](#), adjust with [phosphoric acid](#) to a pH of 3.5, and dilute with [water](#) to 1000 mL.

**Solution A:** [Acetonitrile](#) and *Buffer* (55:45)

**Solution B:** [Acetonitrile](#) and *Buffer* (80:20)

**Mobile phase:** See [Table 1](#).

**Table 1**

Time (min)	Solution A (%)	Solution B (%)
0	100	0
20	100	0
20.1	0	100
40	0	100
40.1	100	0
50	100	0

**Diluent:** [Acetonitrile](#) and [water](#) (70:30)

**Standard stock solution:** 0.1 mg/mL of [USP Dicyclomine Related Compound A RS](#) in *Diluent*. Sonication may be used.

**Standard solution:** 4.0 µg/mL of [USP Dicyclomine Related Compound A RS](#) in *Diluent* from *Standard stock solution*

**Sensitivity solution:** 2.0 µg/mL of [USP Dicyclomine Related Compound A RS](#) in *Diluent* from *Standard solution*

**Sample solution:** Nominally 2.0 mg/mL of dicyclomine hydrochloride in *Diluent* prepared as follows. Transfer NLT 20 Tablets to a tared container, and determine the average Tablet weight. Grind the Tablets to a fine powder using a glass mortar and pestle. Transfer a portion of the powder, equivalent to 200 mg of dicyclomine hydrochloride, to a 100-mL volumetric flask, add about 10 mL of [water](#), and sonicate for at least 2 min to disperse the sample. Add 70 mL of [acetonitrile](#), sonicate for at least 5 min, and shake by mechanical means for at least 30 min. Add 10 mL of [water](#), allow the solution to equilibrate to room temperature, then dilute with [water](#) to volume. Centrifuge a portion of this solution, and use the supernatant.

**Chromatographic system**  
(See [Chromatography \(621\), System Suitability.](#))

**Mode:** LC

**Detector:** UV 215 nm

**Column:** 4.6-mm × 15-cm; 3.5-µm packing [L7](#)

**Flow rate:** 1 mL/min

**Injection volume:** 100 µL

**System suitability**

**Samples:** *Standard solution* and *Sensitivity solution*

**Suitability requirements**

**Relative standard deviation:** NMT 5.0%, *Standard solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of dicyclomine related compound A in the portion of Tablets taken:

Result =  $(r_U/r_S) \times (C_S/C_U) \times 100$

- $r_U$  = peak response of dicyclomine related compound A from the *Sample solution*
- $r_S$  = peak response of dicyclomine related compound A from the *Standard solution*
- $C_S$  = concentration of [USP Dicyclomine Related Compound A RS](#) in the *Standard solution* (mg/mL)
- $C_U$  = nominal concentration of dicyclomine hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** NMT 0.2%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at controlled room temperature.

Add the following:

- ▲ **LABELING:** The labeling states the *Dissolution* test used only if *Test 1* is not used. ▲ (RB 1-Nov-2024)
- **USP REFERENCE STANDARDS (11).**  
[USP Dicyclomine Hydrochloride RS](#)  
[USP Dicyclomine Related Compound A RS](#)  
[1,1'-Bi(cyclohexane)]-1-carboxylic acid.  
 $C_{13}H_{22}O_2$  210.32

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DICYCLOMINE HYDROCHLORIDE TABLETS	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:  
Pharmacopeial Forum: Volume No. PF 43(6)

**Current DocID:** GUID-5E9DB10F-4720-4599-A1D0-70B64397A7EE\_3\_en-US  
**DOI:** <https://doi.org/10.31003/USPNF.M25160.03.01>  
**DOI ref:** [h4ivm](#)